DexCom, Inc. (NASDAQ:DXCM) EVP Andrew K. Balo sold 3,244 shares of the stock in a transaction on Monday, September 11th. The stock was sold at an average price of $72.27, for a total value of $234,443.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Andrew K. Balo also recently made the following trade(s):

  • On Thursday, August 10th, Andrew K. Balo sold 3,244 shares of DexCom stock. The stock was sold at an average price of $71.18, for a total value of $230,907.92.
  • On Monday, July 10th, Andrew K. Balo sold 3,200 shares of DexCom stock. The stock was sold at an average price of $71.55, for a total value of $228,960.00.

Shares of DexCom, Inc. (DXCM) opened at 70.29 on Friday. The stock’s 50 day moving average price is $72.47 and its 200 day moving average price is $74.11. The firm’s market capitalization is $6.08 billion. DexCom, Inc. has a 52 week low of $57.68 and a 52 week high of $94.79.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.07. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The business had revenue of $170.60 million during the quarter, compared to analyst estimates of $166.54 million. During the same quarter in the previous year, the business earned ($0.24) EPS. DexCom’s quarterly revenue was up 24.3% compared to the same quarter last year. On average, analysts predict that DexCom, Inc. will post ($0.77) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Insider Selling: DexCom, Inc. (DXCM) EVP Sells $234,443.88 in Stock” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.dailypolitical.com/2017/09/16/insider-selling-dexcom-inc-dxcm-evp-sells-234443-88-in-stock.html.

Hedge funds have recently added to or reduced their stakes in the stock. Advisor Group Inc. lifted its stake in shares of DexCom by 104.9% in the 2nd quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock valued at $119,000 after purchasing an additional 837 shares during the last quarter. Edmond DE Rothschild Holding S.A. acquired a new stake in shares of DexCom in the 1st quarter valued at $164,000. IFP Advisors Inc lifted its stake in shares of DexCom by 30.5% in the 2nd quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock valued at $178,000 after purchasing an additional 568 shares during the last quarter. Independent Portfolio Consultants Inc. lifted its stake in shares of DexCom by 0.4% in the 2nd quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock valued at $183,000 after purchasing an additional 9 shares during the last quarter. Finally, Daiwa Securities Group Inc. lifted its stake in shares of DexCom by 475.0% in the 1st quarter. Daiwa Securities Group Inc. now owns 2,300 shares of the medical device company’s stock valued at $195,000 after purchasing an additional 1,900 shares during the last quarter.

Several research analysts recently weighed in on DXCM shares. BidaskClub raised DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, June 21st. Cowen and Company reaffirmed a “buy” rating and issued a $90.00 target price on shares of DexCom in a research report on Friday, July 14th. BMO Capital Markets reaffirmed a “buy” rating and issued a $105.00 target price on shares of DexCom in a research report on Thursday, July 13th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $78.00 target price on shares of DexCom in a research report on Monday, May 22nd. Finally, TheStreet raised DexCom from a “d” rating to a “c-” rating in a research report on Wednesday, August 2nd. Seven analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. DexCom presently has a consensus rating of “Buy” and a consensus price target of $86.87.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.